Neoplasms, Urinary Bladder
Conditions
Keywords
Patients, Tumor antigens, Bladder cancer
Brief summary
This study aims to analyze the incidence of expression of MAGE-A3, MAGE-C2, NY-ESO-1, LAGE-1, WT1 and PRAME tumor antigens in cancer tissue from patients with pathologically demonstrated bladder cancer.
Detailed description
There will be no procedure(s) or treatment(s) carried out on patients. All data and samples will be taken from those already stored at the investigation sites. Clinical data collected will include patient demographics (age, gender), Tumor, Node, Metastasis (staging system) \[TNM stage\], and histopathologic description only. Strict anonymity of patient data will be maintained. This retrospective study is based upon the analysis of archived formalin-fixed paraffin-embedded tissue samples and patient-related data already available at the investigational site.
Interventions
Tumor tissue samples submitted for analysis together with a form containing clinical data previously collected and archived from patients with bladder cancer.
Sponsors
GlaxoSmithKline
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
For inclusion of a tissue sample, all of the following criteria must be met: * The patient had pathologically proven bladder cancer (any stage). * All the data required are available from patient's records. There are no restrictions regarding operative technique (cystectomy or cystoscopy). \- Many patients may no longer be alive, or no longer be in contact with the investigation sites. Thus, patients will not be required to give their informed consent before inclusion in the study.
Exclusion criteria
* Not applicable.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the gene expression of MAGE-A3, MAGE-C2, NY-ESO-1, LAGE-1, WT1 and PRAME antigens in pathologically demonstrated bladder cancer. | Up to 1 year |
Countries
Belgium
Outcome results
None listed